Thursday, July 9, 2026

pharma · Familial adenomatous polyposis (FAP) · Familial Adenomatous Polyposis · BDRX

Biodexa Pharmaceuticals

Biodexa Pharmaceuticals clinical programs — 1 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

cardiff, GB HQ
2000 Founded
25 Employees
Public company Type
BDRX · NYSE Ticker
Company details
Status
Public
HQ
cardiff, GB
Founded
2000
Employees
25
Programs
4
Drugs
5
Patents
2
Intelligence · Clinical Programs

Biodexa Pharmaceuticals projects

1 ClinicalTrials.gov programs sponsored by Biodexa Pharmaceuticals.

Biodexa Pharmaceuticals has 1 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. MTX110

    Biodexa Pharmaceuticals Plc

    Recurrent Glioblastoma

    phase 1 small molecule terminated

    1 trial

Frequently asked questions

How many clinical projects does Biodexa Pharmaceuticals have?

1 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.